Evolent Health (EVH) to Release Earnings on Thursday

Evolent Health (NYSE:EVH) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Evolent Health to post earnings of $0.30 per share for the quarter. Evolent Health has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The firm had revenue of $647.10 million during the quarter, compared to analysts’ expectations of $636.46 million. During the same period last year, the firm posted $0.06 EPS. The business’s revenue was up 37.9% on a year-over-year basis. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Evolent Health Trading Up 4.0 %

EVH stock opened at $24.20 on Thursday. The business has a fifty day moving average price of $28.17 and a 200 day moving average price of $25.20. Evolent Health has a fifty-two week low of $17.98 and a fifty-two week high of $35.00. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of -19.36 and a beta of 1.56. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.08 and a quick ratio of 1.08.

Insider Transactions at Evolent Health

In other Evolent Health news, General Counsel Jonathan Weinberg sold 42,140 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $31.20, for a total transaction of $1,314,768.00. Following the transaction, the general counsel now directly owns 167,027 shares in the company, valued at approximately $5,211,242.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Evolent Health news, President Daniel Joseph Mccarthy sold 23,693 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total transaction of $731,876.77. Following the transaction, the president now directly owns 198,809 shares in the company, valued at approximately $6,141,210.01. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jonathan Weinberg sold 42,140 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $31.20, for a total value of $1,314,768.00. Following the transaction, the general counsel now owns 167,027 shares in the company, valued at approximately $5,211,242.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 307,291 shares of company stock worth $9,290,385 in the last three months. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on EVH shares. JPMorgan Chase & Co. increased their price objective on Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. KeyCorp started coverage on Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price objective on the stock. Stephens reiterated an “overweight” rating and issued a $42.00 price objective on shares of Evolent Health in a research report on Tuesday, July 30th. Citigroup decreased their price objective on Evolent Health from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price objective on shares of Evolent Health in a research report on Tuesday, October 8th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Evolent Health currently has a consensus rating of “Buy” and a consensus target price of $38.60.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.